Cite
Hou X, Du H, Quan X, et al. Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway. Front Pharmacol. 2018;9:21doi: 10.3389/fphar.2018.00021.
Hou, X., Du, H., Quan, X., Shi, L., Zhang, Q., Wu, Y., Liu, Y., Xiao, J., Li, Y., Lu, L., Ai, X., Zhan, M., Yuan, S., & Sun, L. (2018). Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway. Frontiers in pharmacology, 921. https://doi.org/10.3389/fphar.2018.00021
Hou, Xiaoying, et al. "Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway." Frontiers in pharmacology vol. 9 (2018): 21. doi: https://doi.org/10.3389/fphar.2018.00021
Hou X, Du H, Quan X, Shi L, Zhang Q, Wu Y, Liu Y, Xiao J, Li Y, Lu L, Ai X, Zhan M, Yuan S, Sun L. Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway. Front Pharmacol. 2018 Feb 08;9:21. doi: 10.3389/fphar.2018.00021. eCollection 2018. PMID: 29472856; PMCID: PMC5809401.
Copy
Download .nbib